ROCO
6578
Market cap37mUSD
Nov 13, Last price
19.80TWD
Name
Dabomb Protein Corp
Chart & Performance
P/E
101.60
P/S
3.50
EPS
0.19
Div Yield, %
2.57%
Shrs. gr., 5y
—
Rev. gr., 5y
-4.28%
Revenues
338m
-12.12%
Net income
12m
P
CFO
48m
+630.93%
Dividend
Jul 30, 20240.50926 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
DaBomb Protein Biotech Corp., a specialized biotech company, primarily engages in the development of antibiotics alternatives in animal health industry. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising LACTOTIDES HEALTH A+ and Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its name to DaBomb Protein Biotech Corp. in October 2023. DaBomb Protein Biotech Corp. was founded in 2001 and is based in Tainan, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||